One of the biopharma company's heart drugs performs as well as initially hoped. Shares of biopharma outfit Edgewise Therapeutics (EWTX 46.88%) soared more than 50% today, reaching a three-year high following an update on the clinical testing of its cardiac drug EDG-7500. The treatment shows promise in two related but distinct trials as a treatment for certain patients with improper bloodflow within the heart. Heart drug EDG-7500 works as hoped On Thursday, Edgewise Therapeutics published data regarding the ...